Oxford Pharmascience Group (OXP)
OXP Share PerformanceMore
|52 week high||7.6220 25/05/16|
|52 week low||1.5000 30/12/16|
|52 week change||-6.0850 (-78.52%)|
|4 week volume||15,833,174 29/04/17|
Media for (OXP)
Latest News« previous» nextMore
09/05/2017 - 07:00 RNS
RNS Number: 5321E Oxford Pharmascience Group PLC 09 May 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Update regarding OXPzeroTM Ibuprofen Programmes Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, pr...
31/03/2017 - 11:49 StockMarketWire
Weaker commodity prices hit miners with Anglo American (AAL), Antofagasta (ANTO) and BHP Billiton (BLT) falling b...
31/03/2017 - 09:05 RNS
RNS Number: 1522B Oxford Pharmascience Group PLC 31 March 2017 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-d...
31/03/2017 - 09:02 StockMarketWire
London shares were a little lower in early deals with heavyweight miners providing decisive ballast, but Old Mutual took t...
31/03/2017 - 09:00 RNS
RNS Number: 1516B Oxford Pharmascience Group PLC 31 March 2017 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before ...
31/03/2017 - 07:44 StockMarketWire
Oxford Pharmascience Group said the US FDA has not agreed with the proposed phase III study design for the OXPzero Ib...
31/03/2017 - 07:00 RNS
RNS Number: 1026B Oxford Pharmascience Group PLC 31 March 2017 31 March 2017 Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") FDA Pre-IND Feedback on OXPzero Ibuprofen Rx programme Oxford Pharmascience Group plc (AIM: OXP), the speciality pharmaceutical company that redevelops medicines to make them better, s...
10/03/2017 - 08:36 StockMarketWire
Oxford Pharmascience has roughly halved its FY pretax loss to 1.9m, from a loss of 3.9m a year earlier. Revenues totalled 7...
|Dividend yield||0 %|
Latest discussion posts More
“That seems logical, I will hold on in the HOPE it passes 2p and take a small profit, if not, leave for 2 or 3 years and most probably have this same conversation again.”▼
“I've bailed after a big hit! The way I read it, they have no product. If they want to release it as planned then they need more trials which could cost millions and also, ...”▼
“I have committed today at 1.7p, my first investment ever in anything outside the FT250. From my understanding of this sector, I don't expect much movement either up or down for ...”▼
Codes & Symbols
|Symbols||OXP, LSE:OXP, OXP.L, OXP:LN, LON:OXP, XLON:OXP|